Phase II/III, randomized, double-blind, double-dummy, placebo-controlled study to evaluate the safety and efficacy of 2 regimens of FP -07321332/Ritonavir administered orally to prevent symptoms of SARS -COV infection -
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: PFIZER, SLU
- Phase: II
- Execution start: 23/09/2021
- End of execution: 30/12/2021
- PI: JUAN PASQUAU LIAÑO